Vaccine may delay recurrence for advanced ovarian cancers
the ONA take:
According to preliminary findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Chicago, Illinois, researchers have found that a vaccine delayed cancer recurrence in women with stage III or IV ovarian cancers.
For the phase II study, researchers enrolled 31 women with stage III or IV ovarian cancer. Of those, 20 received the experimental immunotherapy and 11 did not. Results showed that those who did not receive the immunotherapy experienced a cancer recurrence in a median of 14.5 months, while those who did receive the vaccine have not yet reached the median time to recurrence. Thus far, the majority of the study population is beyond the 14.5 months.
"This was a preliminary study with promising results that may give women with advanced ovarian cancer an option for a maintenance regimen," said Jonathan Oh, MD, a gynecologic oncologist at Texas Oncology, P.A., in Dallas, Texas. "Additionally, the vaccine is very well tolerated."
The findings suggest that using a patient's own immune system to combat advanced ovarian cancer may be promising strategy to improve patient outcomes.
Researchers have found that a vaccine delayed cancer recurrence in women with stage III or IV ovarian cancers.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations
- Parental Self-persuasion in Low-Income Groups Improves HPV Vaccination Rates
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Shared Decision-making Visits Improved Comfort With Lung Cancer Screening Decisions
- Temozolomide With Radiotherapy for Glioblastoma Provides Some Survival Benefit in Elderly
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|